Free Trial
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel
NASDAQ:CYTK

Cytokinetics Q3 2026 Earnings Date & Estimates

Cytokinetics logo
$62.01 +0.89 (+1.46%)
Closing price 04:00 PM Eastern
Extended Trading
$61.54 -0.47 (-0.76%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cytokinetics is scheduled to report Q3 2026 earnings on Wednesday, November 4, 2026, after market closes. The conference call is scheduled for 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Cytokinetics in Q3 2026

Cytokinetics is expected to post earnings of -$1.45 per share on revenue of $39.88 million. In the same quarter a year earlier Cytokinetics reported -$1.54 per share on revenue of $1.94 million. Cytokinetics last reported on August 6, 2026, posting -$1.50 per share and beating the -$1.63 consensus estimate. Cytokinetics has beaten the consensus EPS estimate in 5 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$1.45
Expected Revenue
$39.88 million
Prior-Year EPS
-$1.54
Prior-Year Revenue
$1.94 million
Expected Revenue Growth
+1,960.1%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$1.50 (Beat by +$0.13)
Last Quarter Revenue
$28.62 million
EPS Beat Rate
5 of last 8 quarters

Prepare for the Q3 2026 Call

Cytokinetics Q3 2026 Earnings FAQ

Cytokinetics (NASDAQ:CYTK) is scheduled to report Q3 2026 earnings on Wednesday, November 4, 2026, after market closes.

Cytokinetics' Q3 2026 earnings conference call is scheduled for Wednesday, November 4, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Cytokinetics to post earnings of -$1.45 per share for Q3 2026.

The consensus revenue estimate for Cytokinetics is $39.88 million for Q3 2026.

Cytokinetics Earnings Headlines

Analyzing Cytokinetics (NASDAQ:CYTK) & Pluri (NASDAQ:PLUR)
October 8 at 5:46 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31099223
Cytokinetics (NASDAQ:CYTK) Stock: Insider Fady Ibraham Malik Sells 3,500 Shares
October 8 at 4:52 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31098981
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.tc pixel
October 8 at 1:00 AM  |  Porter & Company (Ad)
Analyzing Zai Lab (NASDAQ:ZLAB) and Cytokinetics (NASDAQ:CYTK)
October 8 at 4:15 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31098816
H.C. Wainwright Sticks to Its Buy Rating for Cytokinetics (CYTK)
October 2, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/CYTK/pressreleases/4908668/hc-wainwright-sticks-to-its-buy-rating-for-cytokinetics-cytk/
Cytokinetics Announces Four Presentations at HFSA 2026 Highlighting Aficamten Data in Hypertrophic Cardiomyopathy
October 2, 2026  |  quiverquant.comQ
See More Cytokinetics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cytokinetics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cytokinetics and other key companies, straight to your email.

About Cytokinetics

Cytokinetics (NASDAQ:CYTK) is a biopharmaceutical company focused on discovering and developing medicines that improve muscle function. The company applies muscle biology and molecular pharmacology to develop therapies for cardiovascular and neuromuscular diseases in which impaired muscle performance contributes to disease progression or disability.

Its lead programs include aficamten, a next-generation cardiac myosin inhibitor being developed for hypertrophic cardiomyopathy, and other investigational compounds designed to modulate the activity of cardiac or skeletal muscle. Cytokinetics has also developed omecamtiv mecarbil, an earlier cardiac myosin activator investigated for heart failure, and reldesemtiv, a skeletal muscle activator studied in neuromuscular disorders.

Founded in 1998, Cytokinetics is headquartered in South San Francisco, California. The company conducts clinical development activities through international studies and has collaborated with larger pharmaceutical companies, including Amgen, on selected programs. Robert I. Blum has served as the company's president and chief executive officer.

View Cytokinetics Profile
Earnings Tools